Annexin Pharmaceuticals Ab Stock Debt To Equity
| ANNX Stock | SEK 0.33 0.02 6.45% |
Annexin Pharmaceuticals AB fundamentals help investors to digest information that contributes to Annexin Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Annexin Stock. The fundamental analysis module provides a way to measure Annexin Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Annexin Pharmaceuticals stock.
Annexin |
Annexin Pharmaceuticals AB Company Debt To Equity Analysis
Annexin Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Annexin Pharmaceuticals Debt To Equity | 1.20 % |
Most of Annexin Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Annexin Pharmaceuticals AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Annexin Pharmaceuticals AB has a Debt To Equity of 1.2%. This is 97.76% lower than that of the Healthcare sector and 93.8% lower than that of the Biotechnology industry. The debt to equity for all Sweden stocks is 97.54% higher than that of the company.
Did you try this?
Run Instant Ratings Now
Instant RatingsDetermine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Annexin Fundamentals
| Return On Equity | -1.06 | |||
| Return On Asset | -0.57 | |||
| Current Valuation | 125.48 M | |||
| Shares Outstanding | 154.5 M | |||
| Shares Owned By Insiders | 45.17 % | |||
| Shares Owned By Institutions | 5.06 % | |||
| Price To Book | 4.90 X | |||
| EBITDA | (50.28 M) | |||
| Net Income | (52.14 M) | |||
| Cash And Equivalents | 22.77 M | |||
| Cash Per Share | 1.29 X | |||
| Debt To Equity | 1.20 % | |||
| Current Ratio | 9.56 X | |||
| Book Value Per Share | 0.20 X | |||
| Cash Flow From Operations | (45.02 M) | |||
| Earnings Per Share | (0.43) X | |||
| Target Price | 2.0 | |||
| Beta | 1.55 | |||
| Market Capitalization | 189.95 M | |||
| Total Asset | 52.79 M | |||
| Net Asset | 52.79 M |
About Annexin Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Annexin Pharmaceuticals AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Annexin Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Annexin Pharmaceuticals AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Annexin Stock Analysis
When running Annexin Pharmaceuticals' price analysis, check to measure Annexin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexin Pharmaceuticals is operating at the current time. Most of Annexin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Annexin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Annexin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.